You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. Hutchmed China upbeat on results from lung cancer trial
- 2. ASCO 20925: Nivolumab plus chemo before surgery improves lung cancer survival
- 3. ASCO 2025: Ramucirumab and pembrolizumab combo does not improve OS for previously treated advanced NSCLC
- 4. Wildfire Smoke Dents Survival Odds For Lung Cancer Patients
- 5. ASCO 2025: Nivolumab plus chemo before surgery improves lung cancer survival
- 6. Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
- 7. Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- 8. China's latest boom is sounding alarm bells in America
- 9. Title of report: second primary ovarian carcinomas after breast cancer diagnosis- an analysis of a single cancer centre in China
- 10. IGF2BP3 enhances ferroptosis resistance in colon cancer by stabilizing SLC7A11 and is regulated by miR-98-5p
Last updated at 8:29 GMT
Hot News Makers
Health/Pharma Companies
-
30709.95
-
25042.04
-
20085.71
-
17776.70
-
14993.52
-
13090.35
-
9840.50
-
7821.31
-
6979.89
-
5419.38
Drugs, Treatments, Trials
-
77950.57
-
20321.42
-
18965.19
-
12168.66
-
9621.08
-
9602.01
-
7602.42
-
4887.27
-
2674.33
-
2548.91
Last updated at 8:10 GMT
